PHARMACOKINETICS News, Sports, Shopping, Travel information

Pharmacokinetics
Looking for Pharmacokinetics? Search over 15,000 sites with one clicks. Your source for everything under the sun!
www.findstuff.com

Anadys Pharmaceuticals Commences Dosing Ana598 In Hepatitis C Patients ... - Msn Moneycentral
san diego , oct. 28 /prnewswire-firstcall/ -- anadys pharmaceuticals, inc. ands announced today that it has initiated dosing ana598 in patients chronically infected with hepatitis c virus (hcv) in a phase ib study. ana598 is an investigational, oral ...
news.moneycentral.msn.com

Phenomix Initiates Phase 1a Clinical Trial Of Hepatitis C Protease Inhibitor
in this double-blind, randomized, placebo-controlled phase 1a study, subjects will be treated with single ascending doses of phx1766 in order to assess safety, tolerability and pharmacokinetics. additionally, reductions in viral load will be measured in the patients with hcv infection.
www.bioresearchonline.com

Xoma Names Doberstein V.p. Of Research Development
berkeley-based xoma ltd., which develops the discovery and development of therapeutic antibodies, announced the appointment of stephen k. doberstein, ph.
www.contracostatimes.com

Pharmathene Initiates Phase I Clinical Trial Of Nerve Agent ... - Msn Moneycentral
annapolis, md. , oct. 27 /prnewswire-firstcall/ -- pharmathene, inc. (nyse alternext us: pip), a biodefense company developing medical countermeasures against biological and chemical threats, today announced that dosing of volunteers has begun in a u ...
news.moneycentral.msn.com

Xoma Names Doberstein V.p. Of Research Development - Contra Costa Times
berkeley-based xoma ltd., which develops the discovery and development of therapeutic antibodies, announced the appointment of stephen k. doberstein, ph.d., to the position of vice president of research. in this position, dr. doberstein will be ...
www.contracostatimes.com

Onconova Announces Publication Of Positive Phase I Results For Lead Anticancer Compound In Journal Of Clinical Oncology
onconova therapeutics, inc. announced today the publication of positive results from a first-in-human phase i clinical trial of its lead anticancer drug, on 01910.na, in advanced refractory solid tumors. the publication will be online today in the journal of clinical oncology and will appear in a future print edition of the journal. a first-in-class targeted therapy, on 01910.
www.medicalnewstoday.com

Phenomix Starts Phase 1a Clinical Trial Of Hepatitis C Protease Inhibitor Phx1766
phenomix corporation today announced it has begun administering subjects in a phase 1a clinical trial of phx1766, the company's internally discovered, orally available ns3/4a protease inhibitor for the treatment of chronic hepatitis c virus (hcv) infection.
www.medicalnewstoday.com

For Tumor Detection Bevacizumab Better Than Gold Standard Imaging - Medical News Today
geneva, switzerland: scientists have developed a new imaging agent that can be used in scanning for tumours, and which gives a much clearer and more precise image than existing methods. the discovery has the potential to revolutionise pre-clinical ...
www.medicalnewstoday.com

Pharmathene Initiates Phase I Clinical Trial Of Nerve Agent ... - Phramalive.com
annapolis, md., october 27, 2008 /prnewswire-firstcall/ -- pharmathene, inc. , a biodefense company developing medical countermeasures against biological and chemical threats, today announced that dosing of volunteers has begun in a u.s. phase i ...
www.pharmalive.com

Seattle Genetics Presents Data On Sgn-70, A Humanized Monoclonal Antibody Targeting Cd70
seattle genetics, inc. (nasdaq: sgen) today presented preclinical data on sgn-70 at the american college of rheumatology (acr) annual scientific meeting in san francisco, california. sgn-70 is a humanized monoclonal antibody targeting cd70 that is in development as a novel therapy for autoimmune diseases.
www.medicalnewstoday.com

Infinity Advances Its Oncology Portfolio And Announces Third Quarter Financial Results
cambridge, mass., oct. 29, 2008 -- infinity pharmaceuticals, inc. , an innovative cancer drug discovery and development company, today provided an update on its pipeline of clinical-stage anti-cancer agents and announced financial results for the third quarter of 2008.
finance.yahoo.com

Significant Anti-tumor Activity, Extended Half-life Of Nktr-102 ... - Emaxhealth.com
mp-470 chemotherapy combined with demonstrates clinical tumor regression socioeconomic status plays role in receiving appropriate lymphoma treatment promising gene target for neuroblastoma therapy identified bisconti to lead drive for patient impact ...
www.emaxhealth.com

Phenomix Initiates Phase 1a Clinical Trial Of Hepatitis C Protease ... - Businesswire.com
san diego--( business wire )--phenomix corporation today announced it has begun administering subjects in a phase 1a clinical trial of phx1766, the company ’ s internally discovered, orally available ns3/4a protease inhibitor for the treatment of ...
www.businesswire.com

Biocryst Reports Positive Results From A Phase 2 Study Of Intravenous Peramivir For Outpatient Influenza
biocryst pharmaceuticals, inc. (nasdaq: bcrx) announced that a double-blind, placebo-controlled, phase 2 study of intravenous (i.v.) peramivir, administered via a single dose injection in outpatients with acute, uncomplicated influenza, met its primary endpoint of time to alleviation of symptoms for both the 300 mg dose (p=0.0046) and 600 mg dose (p=0.0046).
www.medicalnewstoday.com

Northern Antibiotics Presents New Data On Novel Polymyxin Compounds At The Joint Icaac/idsa 2008
northern antibiotics ltd., the developer of novel polymyxin derivatives for the treatment of infections caused by multidrug-resistant gram-negative bacteria, revealed animal efficacy and pharmacokinetic data from their nab compounds at the 48th annual icaac/idsa 46th annual meeting in washington, dc.
www.medicalnewstoday.com

Darunavir Effective And Tolerable In Treatment-experienced Children ... - Aidsmap
the final, 48-week results of a study of darunavir in treatment-experienced, hiv-positive children and adolescents have confirmed earlier findings that the drug is virologically effective and generally well tolerated. the phase ii trial results were ...
www.aidsmap.com

Panacos Presents Phase 2b Bevirimat Data At The 48th Annual ... - Genetic Engineering News
panacos pharmaceuticals, inc. ( nasdaq: panc ), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced that data from the company's phase 2b study of bevirimat, panacos' lead hiv-1 gag ...
www.genengnews.com

Nanocort® Demonstrates Safety And Good Response In Phase I/ii Trial
galapagos nv (euronext: glpg) announces that nanocort has demonstrated safety as well as a faster and more pronounced decrease in rheumatoid arthritis disease symptoms compared to reference medication.
www.bioresearchonline.com

Enzon's Hif-1 Alpha Antagonist Shows Antitumor Activity
enzon pharmaceuticals, inc. (nasdaq: enzn) presented data from its pipeline programs at the 2008 eortc-nci-aacr (european organization for research and treatment of cancer-national cancer institute-american association for cancer research) annual meeting in geneva, switzerland.
www.medicalnewstoday.com

Phenomix Starts Phase 1a Trial Of Hepatitis C Protease Inhibitor - News-medical.net
the study is being conducted at clinical sites in the netherlands and will enroll approximately 24 healthy subjects and six hcv infected patients. in this double-blind, randomized, placebo-controlled phase 1a study, subjects will be treated with ...
www.news-medical.net